Skip to content

A single-center, prospective, randomized controlled clinical trial for comparison between sublobectomy and lobectomy in the surgical treatment of early stage (T1a) invasive adenocarcinoma of the lung

A single-center, prospective, randomized controlled clinical trial for comparison between sublobectomy and lobectomy in the surgical treatment of early stage (T1a) invasive adenocarcinoma of the lung

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900021752
Enrollment
Unknown
Registered
2019-03-08
Start date
2019-04-01
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer

Interventions

Study Group:Sublobectomy
Control Group:Lobectomy

Sponsors

Shanghai Chest Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 75 years; 2. Preoperative thin-section computed tomography (TSCT) will fulfill all of the following conditions: Lesion size is less than 10 mm; 3. Preoperative clinical staging: T1aN0M0 (according to UICC2017-8thTNM staging); 4. R0 resectable in segmentectomy and wedge resections plus hilar/ mediastinal lymph node resection; 5. Preoperative FEV1.0>=1.5 L and >= 50% of the expected value; 6. Performance status of ECOG 0 or 1; 7. Preoperative ASA scoring (American society of anesthesiology) class I -III; 8. The patient agrees to participate in the trial and signs the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Quit smoking <2 weeks; 2. Multiple ground glass nodules with suspect of multiple primary lung cancer; 3. TSCT shows that the lesion is located in the right middle lobe; 4. The lesion is located between two segments with possibility of combined segmental resection; 5. Pregnant or lactating women; 6. Serious mental illness; 7. With other malignant disease history within 5 years; 8. With the history of unstable angina or myocardial infarction within 6 months; 9. With the history of cerebral infarction or cerebral hemorrhage within 6 months; 10. With the history of sustained systemic corticosteroid therapy within 1 month; 11. Other unsuitable situations.

Design outcomes

Primary

MeasureTime frame
5-year Disease-Free Survival;

Countries

China

Contacts

Public ContactQingquan luo/ Jia Huang

Shanghai Chest Hospital

luoqingquan@hotmail.com+86 13003247676 / +86 18017320257

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026